Chantix Information

Chantix in the news because it is an extremely promising new smoking solution that is different than any other smoking aid that has been sold to date. This site, which is unaffiliated with, independent of and not endorsed by Pfizer, Inc., the inventor and trademark holder of the name "Chantix," aims to provide unbiased information to you about Chantix, its promise and any drawbacks. While we can't promise complete coverage or that every detail will be right, we hope to provide a service to the public. And we're not here to preach--all smokers know the health risks of smoking, which is why many may consider a smoking-cessation aid like Chantix. Most information about Chantix available on the Internet falls into one of two categories. First, hard-sell advertisements by people trying to sell the drug. Second, overly technical data designed for experts or those who are already familiar with the issues surrounding Chantix. The goal of this site is to be in neither of these categories, but rather to be useful and up-to-date for the average person. Is Chantix Available For Sale Now? Yes. It went on sale in August, 2006 in the United States. Chantix is awaiting approval from European regulators. Learn more about buying Chantix (varenicline). What Are The Possible Benefits of Chantix? Although some dispute the studies, the possible benefit of Chantix is simple--it appears that it can help people quit smoking much more effectively than current therapies. According to a study reported in the prestigious Journal of the American Medical Association in July, 2006 Chantix (varenicline) can be four times as effective in helping a smoker give up cigarettes successfully. Moreover, in that study Chantix was twice as effective as Zyban (bupropion). Learn more about the possible benefits of Chantix. What Are The Possible Risks and Side Effects of Chantix? The most common side effects of Chantix seen in clinical trials include nausea, headache and vomiting. By far the main side effect with Chantix is nausea, although researchers ...